Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 3, 2016Haemophilia

Recombinant long‐acting glyco PEG ylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials

View Full Paper
Ask AI
Bookmark
Share

Authors

CNClaude NégrierUniversité Claude Bernard Lyon 1GYGuy YoungUniversity of Southern CaliforniaFKFaraizah Abdul KarimKuala Lumpur Sports Medicine Centre

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Négrier et al. (2016) studied this question.

synapsesocial.com/papers/6a9228313da4caa5ce962e57https://doi.org/10.1111/hae.12902
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The impact of prophylactic treatment on children with severe haemophilia1996 · 189 citations
  2. 2A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs1994 · 617 citations
  3. 3Definitions for haemophilia prophylaxis and its outcomes: The Canadian Consensus Study2006 · 52 citations
  4. 4A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres2003 · 67 citations